[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.213.148. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 335
Citations 0
Clinical Trials Update
November 24, 2015

Eltrombopag Benefits Children With Chronic Immune Thrombocytopenia

JAMA. 2015;314(20):2122. doi:10.1001/jama.2015.15714

The thrombopoietin receptor agonist eltrombopag, which has been approved to treat adults with chronic immune thrombocytopenia, is safe and effective in children, according to the phase 3 PETIT2 trial conducted at 38 centers in 12 countries (Grainger JD et al. Lancet. doi:10.1016/S0140-6736(15)61107-2 [published online July 28, 2015]). Immune thrombocytopenia, an autoimmune disease that destroys platelets, can lead to excessive bruising or bleeding. Approximately 5 in 100 000 children have the disease, with 13% to 36% developing chronic immune thrombocytopenia. The most common treatments include immunosuppression with corticosteroids, rituximab, and splenectomy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×